Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models

作者：Shenshen Wu, Jun Yeon Yun, Weiyan Tang, Giuseppe Familiari, Michela Relucenti, Jiong Wu, Xiaobo Li, Han-Qing Chen, Rui Chen · 发表于：ACS Nano · 年份：2023 · DOI：10.1021/acsnano.3c03050 · 被引用次数：98 · 研究领域：RNA modifications and cancer、MicroRNA in disease regulation、RNA Research and Splicing

Although therapeutic targets have been developed for colorectal cancer (CRC) therapy, the therapeutic effects are not ideal and the survival rate for CRC patients remains poor. Therefore, it is crucial to recognize a specific target and develop an efficacious delivery system for CRC therapy. Herein, we demonstrate that reduced ALKBH5 mediates aberrant m 6 A modification and tumor progression in CRC. Mechanically, histone deacetylase 2-mediated H3K27 deacetylation inhibits ALKBH5 transcription in CRC, whereas ectopic ALKBH5 expression decreases tumorigenesis of CRC cells and protects mice from colitis-associated tumor development. Further, METTL14/ALKBH5/IGF2BPs combine to modulate JMJD8 stability in an m 6 A-dependent manner, which increases glycolysis and accelerates the development of CRC by enhancing the enzymatic activity of PKM2. Moreover, ALKBH5 mRNA-loaded folic acid-modified exosome–liposome hybrid nanoparticles were synthesized and significantly inhibit the progression of CRC in preclinical tumor models by modulating the ALKBH5/JMJD8/PKM2 axis and inhibiting glycolysis. Overall, our research confirms the crucial function of ALKBH5 in regulating the m 6 A status in CRC and provides a direct preclinical approach for using ALKBH5 mRNA nanotherapeutics for CRC.